Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
395 studies found for:    "primary myelofibrosis"
Show Display Options
Rank Status Study
21 Completed A Phase 2 Study With IPI-926 in Patients With Myelofibrosis
Conditions: Primary Myelofibrosis;   Fibrosis, Bone Marrow
Intervention: Drug: IPI-926
22 Unknown  Assessment of Labile Plasma Iron (LPI) in Myelodysplastic Syndromes (MDS) and Primary Myelofibrosis
Conditions: Myelodysplastic Syndrome;   Primary Myelofibrosis
Intervention:
23 Completed
Has Results
Ph II Study of Azacitidine in Myelofibrosis
Condition: Myelofibrosis
Intervention: Drug: Azacitidine
24 Recruiting Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis
Conditions: Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase;   Primary Myelofibrosis
Interventions: Biological: Durvalumab;   Other: Laboratory Biomarker Analysis
25 Active, not recruiting Study of Ruxolitinib for Patients With Myelofibrosis (MF)
Condition: Myelofibrosis
Interventions: Drug: Ruxolitinib;   Behavioral: Questionnaires
26 Recruiting A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
Condition: Myelofibrosis
Interventions: Drug: INCB050465;   Drug: Ruxolitinib
27 Completed
Has Results
A Phase II Study of CC-5013 in Myelofibrosis
Condition: Myelofibrosis
Intervention: Drug: CC-5013
28 Not yet recruiting A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Condition: Myelofibrosis
Interventions: Drug: Itacitinib;   Drug: Ruxolitinib
29 Terminated
Has Results
Phase II Study of Bevacizumab (Avastin®) in Myelofibrosis
Condition: Myelofibrosis
Intervention: Drug: bevacizumab (Avastin)
30 Active, not recruiting Allogeneic Stem Cell Transplantation for Myelofibrosis
Condition: Myelofibrosis
Interventions: Drug: Busulfan;   Drug: Fludarabine;   Drug: Thymoglobulin (ATG)
31 Active, not recruiting A Study to Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary Myelofibrosis
Condition: Myelofibrosis
Interventions: Drug: INC424;   Drug: BKM120
32 Completed A Trial of Zoledronic Acid in Patients With Myelofibrosis With Myeloid Metaplasia (MMM)
Conditions: Myelofibrosis;   Myeloid Metaplasia
Intervention: Drug: zoledronic acid
33 Completed
Has Results
Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis
Condition: Myelofibrosis
Intervention: Drug: Fludarabine, Melphalan +/- ATG
34 Recruiting Quantitative MRI for Myelofibrosis
Condition: Myelofibrosis
Intervention: Procedure: T1 Weighted MRI (magnetic resonance imaging)
35 Recruiting Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis
Condition: Myelofibrosis
Interventions: Drug: PIM447;   Drug: Ruxolitinib;   Drug: LEE011
36 Active, not recruiting Study to Compare Busulfan-fludarabine With Thiotepa-fludarabine Regimen in Allogeneic Transplantation for Myelofibrosis
Condition: Myelofibrosis
Interventions: Drug: A: Fludarabine + Busulphan;   Drug: B: Fludarabine + Thiotepa
37 Completed Pilot Trial of Arsenic + Cytarabine in Patients With Myelofibrosis
Condition: Myelofibrosis
Interventions: Drug: arsenic trioxide;   Drug: cytarabine
38 Recruiting A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis
Condition: Myelofibrosis
Interventions: Drug: Ruxolitinib;   Drug: Thalidomide
39 Completed Allogeneic Stem Cell Transplantation (SCT) After Dose-reduced Conditioning for Myelofibrosis Patients
Condition: Myelofibrosis
Intervention: Procedure: Allogeneic Stem Cell Transplantation
40 Recruiting PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis
Conditions: Primary Myelofibrosis;   Myeloproliferative Disorders
Interventions: Procedure: Allogeneic hematopoietic stem cell transplantation;   Drug: Busulfan;   Drug: Fludarabine monophosphate;   Drug: Cyclophosphamide;   Drug: Ruxolitinib

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.